For those that are interested, here's the details and abstract for the Oncolytic Virus Data poster presentation:

AACR Annual Meeting 2021 Online Proceedings and Itinerary Planner | Presentation (abstractsonline.com)

Session PO.ET08.01 - Gene and Vector-Based Therapy

1155 - Subcutaneous intratumoral administration of a novel oncolytic virus leads to eradication of peritoneal disseminated pancreatic cancer in nude mice

	April 10, 2021, 8:30 AM - 11:59 PM	Poster

Presenter/AuthorsZhifang Zhang,Annie Yang,Shyambabu Chaurasiya,Sang-In Kim,Anthony K. Park,Jianming Lu,Susanne G. Warner,Yuman Fong,Yanghee Woo. City of Hope National Medical Center, Duarte, CA, City of Hope National Medical Center, Duarte, CADisclosures Z. Zhang:None. A. Yang:None. S. Chaurasiya:None. S. Kim:None. A.K. Park:None. J. Lu:None. S.G. Warner:None. Y. Fong:None. Y. Woo:None.AbstractIntroduction:We investigated a novel oncolytic virus, CF33-hNIS-antiPDL1, which has shown robust preclinical activity against numerous solid tumors, for its ability to track and kill distant peritoneal metastases after local virus administration in vivo.
Methods:In this study, we used CF33-hNIS-antiPDL1, a replication competent orthopoxviral chimera engineered to express the human sodium iodine symporter (hNIS) and anti-human programmed death ligand 1 (PD-L1) antibody. To create our mouse model, we inoculated the human pancreatic cell line - AsPC1-ffluc (5x10⁶cells/site) in both the subcutaneous space and the peritoneum in nude mice. After confirming presence of tumor, the mice were divided into two groups; and treated with either 1) three doses of intratumoral (IT) CF33-hNIS-antiPDL1 (3x10⁵plaque forming units; (n=8) or 2) PBS (n=4). Each mouse was assessed for the following: tumor burden (bioluminescence imaging); CF33-hNIS-antiPDL1 tracking and replication in tumors (¹²⁴I based PET imaging); and survival (time to death).
Results:By week 2, the animals in the CF33-hNIS-antiPDL1 treated group compared to the PBS treated group had significantly decreased tumor burden both in the peritoneal tumors (2.5e9±2.498e9 %/ID/cc versus 1.6e10 ±1.3e10 %/ID/cc, respectively; p<0.05) and SC tumors (5.2e8 ±4.3e8 %/ID/cc versus 2.6e9 ±2.6e9 %/ID/cc; p<0.05). With a median survival of 35 days, all PBS treated mice died from disease between 21 to 47 days. In the CF33-hNIS-antiPDL1 treated group, the median survival was 49 days; and two out of eight mice were still alive at 220 days (p<0.05). These two surviving animals had no evidence of cancer; there was complete eradication of SC and peritoneal tumors. At one week after the first CF33-hNIS-antiPDL1 administration, significantly increased PET avidity for¹²⁴I uptake in the SC tumors (6.4±1.5 photons/second of regions of interest) and PC tumors (3.5±0.14 photons/second of regions of interest) were visible in the CF33-hNIS-antiPDL1 treated mice.
Conclusion:After local SC tumor injection, CF33-hNIS-antiPDL1 can efficiently kill local tumor and kill distant peritoneal metastases to improve survival. Successful therapy of SC and peritoneal tumors using CF33-hNIS-antiPDL1 can be visualized by¹²⁴I-based PET imaging.
I imagine Imugene will release the actual poster over the weekend (or to the ASX on Monday).